NASDAQ:RPRX - Repros Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.67 -0.01 (-1.47 %) (As of 07/20/2018 02:30 AM ET)Previous Close$0.6765Today's Range$0.6650 - $0.675052-Week Range$0.26 - $1.33Volume251,774 shsAverage Volume473,590 shsMarket Capitalization$26.50 millionP/E RatioN/ADividend YieldN/ABeta0.45 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids. Receive RPRX News and Ratings via Email Sign-up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryPharmaceuticals SectorN/A SymbolNASDAQ:RPRX CUSIP76028H20 Webwww.zonagen.com Phone+1-281-7193400 Debt Debt-to-Equity RatioN/A Current Ratio1.18 Quick Ratio1.18 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$50,000.00 Price / Sales530.10 Cash FlowN/A Price / CashN/A Book Value$0.24 per share Price / Book2.79 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-17,270,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-134.23% Miscellaneous Employees24 Outstanding Shares39,560,000Market Cap$26.50 Repros Therapeutics (NASDAQ:RPRX) Frequently Asked Questions What is Repros Therapeutics' stock symbol? Repros Therapeutics trades on the NASDAQ under the ticker symbol "RPRX." How were Repros Therapeutics' earnings last quarter? Repros Therapeutics Inc (NASDAQ:RPRX) released its quarterly earnings results on Monday, November, 13th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.24. The biotechnology company had revenue of $0.30 million for the quarter. View Repros Therapeutics' Earnings History. What price target have analysts set for RPRX? 1 analysts have issued 1-year price objectives for Repros Therapeutics' shares. Their predictions range from $0.39 to $0.39. On average, they anticipate Repros Therapeutics' share price to reach $0.39 in the next year. This suggests that the stock has a possible downside of 41.8%. View Analyst Ratings for Repros Therapeutics. What is the consensus analysts' recommendation for Repros Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repros Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." Who are Repros Therapeutics' key executives? Repros Therapeutics' management team includes the folowing people: Patrick P. Fourteau, Chairman of the Board (Age 69)Larry M Dillaha M.D., President, Chief Executive Officer, Director (Age 53)Katherine A. Anderson CPA, Chief Financial Officer, Chief Accounting Officer, Secretary (Age 58)Joachim F. Wernicke, Chief Medical Officer (Age 68)Daniel F. Cain, Independent Director (Age 70)Nola E. Masterson, Independent Director (Age 69)Saira Ramasastry, Independent Director (Age 40)Michael G. Wyllie Ph.D., Independent Director (Age 65) Has Repros Therapeutics been receiving favorable news coverage? Media coverage about RPRX stock has been trending somewhat negative recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Repros Therapeutics earned a media sentiment score of -0.01 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 44.99 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. How do I buy shares of Repros Therapeutics? Shares of RPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Repros Therapeutics' stock price today? One share of RPRX stock can currently be purchased for approximately $0.67. How big of a company is Repros Therapeutics? Repros Therapeutics has a market capitalization of $26.50 million and generates $50,000.00 in revenue each year. Repros Therapeutics employs 24 workers across the globe. How can I contact Repros Therapeutics? Repros Therapeutics' mailing address is 2408 Timberloch Pl Ste B7, THE WOODLANDS, TX 77380-1021, United States. The biotechnology company can be reached via phone at +1-281-7193400 or via email at [email protected] MarketBeat Community Rating for Repros Therapeutics (NASDAQ RPRX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 184 (Vote Outperform)Underperform Votes: 138 (Vote Underperform)Total Votes: 322MarketBeat's community ratings are surveys of what our community members think about Repros Therapeutics and other stocks. Vote "Outperform" if you believe RPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RPRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What do investors mean by earnings per share?